Torrent Pharma
Ticker > Company >

Torrent Pharma share price

Torrent Pharmaceuticals Ltd.

NSE: TORNTPHARM BSE: 500420 SECTOR: Pharmaceuticals & Drugs  123k   267   21

3409.75
+8.55 (0.25%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 3429

Today's Low

₹ 3375.5

52 Week High

₹ 3589.95

52 Week Low

₹ 2248.7

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 115401.43 Cr.

Enterprise Value

₹ 118625.63 Cr.

No. of Shares

33.84 Cr.

P/E

70.54

P/B

15.33

Face Value

₹ 5

Div. Yield

0.82 %

Book Value (TTM)

₹  222.38

CASH

₹ 108.76 Cr.

DEBT

₹ 3332.96 Cr.

Promoter Holding

71.25 %

EPS (TTM)

₹  48.34

Sales Growth

10.89%

ROE

20.43 %

ROCE

20.96%

Profit Growth

29.07 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Torrent Pharmaceuticals Ltd.

Losar Shelcal Molnutor

Index Presence

The company is present in 31 Indices.

NIFTYJR

Nifty Next 50
69165.85
  308.600000000006 (0.448173576493405%)

NIFTY100WEIGHT

Nifty100 Equal Weight
31426.05
  109.799999999999 (0.350616692611672%)

NFTALLO30

NIFTY Alpha Low-Volatility 30
27407.95
  46.4000000000015 (0.16958103616207%)

NT200ALP30

NIFTY200 Alpha 30
26389.75
  171.700000000001 (0.654892335623747%)

NIFTY100

Nifty 100
24611.35
  38.8499999999985 (0.158103571065205%)

NFTALQVL30

NIFTY Alpha Quality Low-Volatility 30
22740.65
  1.90000000000146 (0.00835578033093753%)

NIFTYPHARMA

Nifty Pharma
22712.55
  153.649999999998 (0.68110590498649%)

NIFTY500

Nifty 500
22430.35
  27.6499999999978 (0.123422623165959%)

NT100LOW30

Nifty100 Low Volatility 30
19199.55
  15.2999999999993 (0.0797529223190763%)

NT100ALP30

NIFTY100 Alpha 30
18582.55
  111.950000000001 (0.606098340064753%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17579.15
  11.9000000000015 (0.0677396860635726%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15803.2
  14.2000000000007 (0.0899360314142728%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
15734.4
  18.2999999999993 (0.116441101800069%)

NIFTYHEALTH

Nifty Healthcare Index
14582.8
  113.199999999999 (0.782329850168617%)

NFT500EQUAL

Nifty 500 Equal Weight
14161.25
  -7.5 (-0.0529333921482134%)

NIFTYMFG

NIFTY India Manufacturing
13845.4
  47.8999999999996 (0.347164341366191%)

NIFTY200

Nifty 200
13456.35
  20.3500000000004 (0.15145876749032%)

NIFTYTOTALMCAP

NIFTY Total Market
12662
  11.4500000000007 (0.0905098987791009%)

NIFTY100ESG

NIFTY100 ESG
4709.65
  9.54999999999927 (0.20318716623049%)

NIFTY100ESGSECT

Nifty100 ESG Sector Leaders
3954.65
  5.25 (0.132931584544482%)

MIDCAP

Bse MidCap
46364.51
  50.4900000000052 (0.109016664932149%)

BSE HC

Bse Healthcare
44289.95
  197.909999999996 (0.448856528298514%)

BSE500

Bse 500
35265.03
  42.3799999999974 (0.120320305258126%)

200EQW

BSE 200 Equal Weight
12654.12
  22.9100000000017 (0.181376131027844%)

BSE200

Bse 200
10972.37
  16.0400000000009 (0.14639938738612%)

LMI250

Bse 250 LargeMidCap Index
10414.25
  14.5100000000002 (0.139522718837193%)

BSE100LARGECAPTMC

Bse 100 LargeCap TMC Index
8868.13
  13.2799999999988 (0.149974307865164%)

SPBSQIP

Bse Quality Index
1793.12
  2.73999999999978 (0.153040136730742%)

ALLCAP

Bse Allcap
10471.31
  71.0699999999997 (0.683349615008888%)

S&P LARGEMIDCAP

Bse LargeMidCap
10285.25
  -7.07999999999993 (-0.0687890885737286%)

S&P MIDSMLCAP

Bse MidSmallCap
13523.19
  31.9400000000005 (0.236746039099422%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.89%
3 Year9.77%
5 Year8.17%

Profit Growth

1 Year29.07%
3 Year6.05%
5 Year12.73%

ROE%

1 Year20.43%
3 Year17.63%
5 Year18.36%

ROCE %

1 Year20.96%
3 Year18.67%
5 Year17.39%

Debt/Equity

0.4881

Price to Cash Flow

39.89

Interest Cover Ratio

7.3245

CFO/PAT (5 Yr. Avg.)

1.90848532215299

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 71.25 0.00
Jun 2024 71.25 0.00
Mar 2024 71.25 0.00
Dec 2023 71.25 0.00
Sep 2023 71.25 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 31.85978976395% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 4.26339999999999 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.90848532215299.
  • The company has a high promoter holding of 71.25%.

 Limitations

  • The company has shown a poor profit growth of 6.04905724790707% for the Past 3 years.
  • The company has shown a poor revenue growth of 9.77390563268261% for the Past 3 years.
  • The company is trading at a high PE of 70.54.
  • The company is trading at a high EV/EBITDA of 35.4732.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 2146 2123 2143 2438 2434
Total Expenditure 1410 1422 1427 1539 1513
Operating Profit 736 701 716 899 921
Other Income 15 -11 76 21 -7
Interest 77 69 67 64 54
Depreciation 192 191 195 189 190
Exceptional Items 0 0 0 0 0
Profit Before Tax 482 430 530 667 670
Tax 155 133 120 198 210
Profit After Tax 327 297 410 469 460
Adjusted EPS (Rs) 9.66 8.78 12.11 13.86 13.59

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 6168.44 6450.57 6742.32 7695.2 8532.9
Total Expenditure 4251.45 4258.84 4641.6 5230.04 5643.73
Operating Profit 1916.99 2191.73 2100.72 2465.16 2889.17
Other Income 236.93 118.34 204.21 81.88 91.49
Interest 430.49 334.12 236.29 297.68 303.04
Depreciation 606.66 609.84 602.43 672.34 761.05
Exceptional Items 0 0 0 0 0
Profit Before Tax 1116.77 1366.11 1466.21 1577.02 1916.57
Tax 178.26 228.26 474.76 525.63 559.49
Net Profit 938.51 1137.85 991.45 1051.39 1357.08
Adjusted EPS (Rs.) 27.73 33.62 29.29 31.06 40.1

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 84.62 84.62 84.62 169.23 169.23
Total Reserves 5036.35 5945.48 6260.8 6286.73 6659.53
Borrowings 3139.99 2941.07 1971.6 2331.78 1603.78
Other N/C liabilities 168.27 175.74 412.18 675.04 955.45
Current liabilities 3387.48 2585.8 2423.36 3409.15 2988.6
Total Liabilities 11816.71 11732.71 11152.56 12871.93 12376.59
Assets
Net Block 7197.5 6741.24 6251.25 7971.85 7985.92
Capital WIP 513.33 554.84 543.54 674.9 203.94
Intangible WIP 23.08 33.27 23.96 23.03 22.29
Investments 134.87 174.87 183.66 205.12 322.27
Loans & Advances 100.91 75.61 65.3 68.42 95.24
Other N/C Assets 27.76 11 151.45 1.53 5.87
Current Assets 3819.26 4141.88 3933.4 3927.08 3741.06
Total Assets 11816.71 11732.71 11152.56 12871.93 12376.59
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1116.77 1366.11 1466.21 1577.02 1916.57
Adjustment 857.08 884.8 827.91 990.49 957.61
Changes in Assets & Liabilities -187.25 -468.12 86.25 -29.64 343.6
Tax Paid -206.7 -209.9 -240.27 -272.46 -324.68
Operating Cash Flow 1579.9 1572.89 2140.1 2265.41 2893.1
Investing Cash Flow 269.43 -316.28 -159.7 -2325.75 -296.07
Financing Cash Flow -1555.48 -1581.2 -1977.27 80.74 -2577.57
Net Cash Flow 293.85 -324.59 3.13 20.4 19.46

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 71.25 71.25 71.25 71.25 71.25
torrent investments priva... 71.25 71.25 71.25 71.25 71.25
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 28.75 28.75 28.75 28.75 28.75
investor education and pr... - - 0.11 - 0.11
nps trust - - - - 1.32
investor education and pr... 0.11 0.11 - 0.11 -
kotak mahindra trustee co... - - 1.02 - -
kotak equity hybrid 1.20 1.21 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Torrent Pharma enters into agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands 5 Dec, 11:12 AM Torrent Pharma - Quaterly Results 25 Oct, 5:18 PM Torrent Pharma - Quaterly Results 25 Oct, 5:18 PM Torrent Pharma - Quaterly Results 25 Oct, 5:18 PM Torrent Pharmaceuticals incorporates Wholly owned subsidiary in Chile 27 Sep, 9:47 AM Torrent Pharmaceuticals raises Rs 200 crore through Commercial Papers 21 Sep, 2:27 PM Torrent Pharmaceuticals gets EIR with VAI classification for Gujarat manufacturing facility 30 Aug, 11:10 AM Torrent Pharmaceuticals informs about disclosure 30 Aug, 9:44 AM Torrent Pharmaceuticals informs about clarification 14 Aug, 12:54 PM Torrent Pharmaceuticals informs about change in management 13 Aug, 12:10 PM Torrent Pharmaceuticals reports 21% rise in Q1 consolidated net profit 24 Jul, 12:14 PM Torrent Pharma - Quaterly Results 23 Jul, 5:20 PM Torrent Pharma - Quaterly Results 23 Jul, 5:20 PM Torrent Pharma - Quaterly Results 23 Jul, 5:20 PM Torrent Pharmaceuticals informs about conference call 18 Jul, 2:28 PM Torrent Pharmaceuticals informs about details of loss of certificate 13 Jun, 12:47 PM USFDA completes inspections at Torrent Pharmaceuticals’ Gujarat manufacturing facility 13 Jun, 10:23 AM Torrent Pharmaceuticals enters into patent licensing agreement with Takeda 5 Jun, 4:21 PM Torrent Pharma - Quaterly Results 24 May, 5:48 PM Torrent Pharma - Quaterly Results 24 May, 5:48 PM USFDA issues EIR to Torrent Pharmaceuticals’ Gujarat facility 6 Mar, 10:13 AM Torrent Pharmaceuticals reports 52% rise in Q3 consolidated net profit 3 Feb, 2:36 PM Torrent Pharmaceuticals informs about presentation 2 Feb, 2:23 PM Torrent Pharma - Quaterly Results 2 Feb, 1:53 PM Torrent Pharma - Quaterly Results 2 Feb, 1:53 PM Torrent Pharma - Quaterly Results 2 Feb, 1:53 PM Torrent Pharmaceuticals informs about board meeting 12 Jan, 11:14 AM Torrent Pharmaceuticals incorporates Wholly Owned Subsidiary in Colombia 5 Jan, 9:01 AM USFDA concludes pre-approval inspection at Torrent Pharmaceuticals’ Gujarat facility 12 Dec, 9:23 AM Torrent Pharmaceuticals informs about press release 6 Dec, 4:15 PM Torrent Pharmaceuticals informs about press release 10 Nov, 4:30 PM Torrent Pharmaceuticals enters into licensing and supply agreement with Zydus Lifesciences 10 Nov, 3:27 PM Torrent Pharmaceuticals informs about issuance of duplicate share certificates 9 Nov, 2:37 PM Torrent Pharmaceuticals informs about transcript of conference call 26 Oct, 1:12 PM Torrent Pharmaceuticals reports 24% rise in Q2 consolidated net profit 25 Oct, 12:42 PM Torrent Pharma - Quaterly Results 23 Oct, 5:49 PM Torrent Pharma - Quaterly Results 23 Oct, 5:49 PM Torrent Pharma - Quaterly Results 23 Oct, 5:49 PM Torrent Pharmaceuticals informs about issuance of duplicate share certificates 15 Sep, 2:31 PM Torrent Pharmaceuticals informs about press release 24 Aug, 1:01 PM Torrent Pharmaceuticals gets EIR for Dahej manufacturing facility 24 Aug, 9:44 AM Torrent Pharmaceuticals informs about disclosure 24 Aug, 9:28 AM Torrent Pharmaceuticals commences commercial operations of Oral Oncology facility at Gujarat 8 Aug, 10:58 AM Torrent Pharma - Quaterly Results 7 Aug, 4:40 PM Torrent Pharma - Quaterly Results 7 Aug, 4:40 PM Torrent Pharma - Quaterly Results 7 Aug, 4:40 PM Torrent Pharmaceuticals informs about annual report 14 Jul, 5:05 PM Torrent Pharmaceuticals gets EIR for Gujarat Oral-Oncology manufacturing facility 16 Jun, 11:51 AM Torrent Pharmaceuticals informs about conference call transcript 3 Jun, 3:32 PM Torrent Pharma - Quaterly Results 30 May, 4:56 PM

Torrent Pharma Stock Price Analysis and Quick Research Report. Is Torrent Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Torrent Pharma and its performance over the period of time. Torrent Pharma stock price today is Rs 3421.35.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Torrent Pharma cash from the operating activity was Rs 2893.1 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Torrent Pharma has a Debt to Equity ratio of 0.4881 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Torrent Pharma , the EPS growth was 29.0749 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Torrent Pharma has OPM of 33.8591803490021 % which is a good sign for profitability.
     
  • ROE: Torrent Pharma have a healthy ROE of 20.4307 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Torrent Pharma is Rs 3421.35. One can use valuation calculators of ticker to know if Torrent Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Torrent Pharma

Torrent Pharmaceuticals Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Torrent Pharmaceuticals Ltd. is a leading Indian pharmaceutical company that has been providing quality healthcare products to its customers for over five decades. In this article, we will provide a comprehensive analysis of Torrent Pharmaceuticals Ltd. stock from a long-term investor's perspective. We will cover various topics such as share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Torrent Pharmaceuticals Ltd. Share Price:

Torrent Pharmaceuticals Ltd.'s share price is a key indicator of investor sentiment towards the company. The share price is influenced by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to analyze Torrent Pharmaceuticals Ltd.'s share price and identify any trends or patterns. The company's share price has shown a stable trend over the past few years, reflecting the company's solid financial position and growth prospects.

Torrent Pharmaceuticals Ltd. Balance Sheet:

Torrent Pharmaceuticals Ltd.'s balance sheet provides crucial information about its financial health. The company's assets include fixed assets, investments, and other assets, while liabilities include loans, borrowings, and other liabilities. Equity includes share capital, reserves, and surplus. Long-term investors can use our pre-built screening tools to analyze Torrent Pharmaceuticals Ltd.'s balance sheet and identify any red flags. The company's balance sheet has shown a stable trend over the past few years, reflecting the company's solid financial position and growth prospects. 

Torrent Pharma reserves growth  

There is a slight rise in the overall reserves as can be seen from its beginning balance in March 2020 at Rs  5,036.35 crores to March 2024 at Rs  6,659.53 crores. This constant increase is an indication of the company’s efforts to improve its ‘balance sheet’ and also to increase shareholder’s worth.

Torrent Pharma Debt Position  

The outstanding borrowings of Torrent Pharma have been reduced from Rs 3,139.99 crores as of the balance in March 2020 to Rs 1,603.78 crores in the balance as of March 2024. This decline points to the fact that the company has embraced the strategy of lowering its debt levels with the aim of making it more financially secure.

Torrent Pharma – Current Liabilities  

The current liabilities have shown some variation where the maximum level was Rs 3,409.15 crores as on 31/03/2023 and a minimum was Rs 2,988.60 crores as on 31/03/2024. This trend simply shows that Torrent Pharma is in a way, managing its near-term liabilities as well as an organization’s operating requirements.

Torrent Pharma: A Brief of Assets  

In Torrent Pharma total assets have slightly reduced from Rs 11,816.71 crore in March 2020 to Rs 12,376.59 crore in March 2024. Of interest is that the net block has been less fluctuating, suggesting continuous investment in structures, whereas the current assets have been changing slightly, implying a concern with high liquidity.

More specifically, it only considers the balance sheet of Torrent Pharma, to make a clear assessment on its financial health and future development prognosis. There are tensions that the changes in the pharmaceutical industry may cause shifts in the company’s strategic standing, so investors may wish to monitor such shifts in the pharmaceutical segment.

Torrent Pharmaceuticals Ltd. Annual Report:

Torrent Pharmaceuticals Ltd. releases an annual report every year, which provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Long-term investors can download Torrent Pharmaceuticals Ltd.'s annual report from our website and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Torrent Pharmaceuticals Ltd. Dividend:

Torrent Pharmaceuticals Ltd. has a consistent dividend payout history. The company has paid dividends in every year, reflecting its commitment to rewarding shareholders. Long-term investors should consider this when evaluating Torrent Pharmaceuticals Ltd.'s stock. Our pre-built screening tools can be used to analyze the company's dividend history and identify any trends or patterns.

Torrent Pharmaceuticals Ltd. Quarterly Results:

Torrent Pharmaceuticals Ltd. releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Long-term investors can use our pre-built screening tools to analyze Torrent Pharmaceuticals Ltd.'s quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Torrent Pharmaceuticals Ltd. Stock Price:

The stock price of Torrent Pharmaceuticals Ltd. is affected by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to track Torrent Pharmaceuticals Ltd.'s stock price and identify potential buying opportunities. The stock price of Torrent Pharmaceuticals Ltd. has shown a stable trend over the past few years, reflecting the company's solid financial performance and growth prospects.

Torrent Pharmaceuticals Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Long-term investors can use our pre-built screening tools to analyze Torrent Pharmaceuticals Ltd.'s price chart and identify any trends or patterns. The price chart shows that the stock price of Torrent Pharmaceuticals Ltd. has shown a stable trend over the past few years, reflecting the company's solid financial performance and growth prospects.

Torrent Pharmaceuticals Ltd. News:

Keeping up to date with the latest news about Torrent Pharmaceuticals Ltd. is important for investors. Our website provides the latest news about Torrent Pharmaceuticals Ltd. from various sources such as financial news websites and social media. Long-term investors can use this information to make informed investment decisions.

Torrent Pharmaceuticals Ltd. Concall:

Torrent Pharmaceuticals Ltd. holds conference calls with analysts and investors to discuss its financial performance and future plans. Long-term investors can listen to Torrent Pharmaceuticals Ltd.'s concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Torrent Pharmaceuticals Ltd. Transcripts:

Transcripts of Torrent Pharmaceuticals Ltd.'s concalls are available on our website. Long-term investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Torrent Pharmaceuticals Ltd. Investor Presentations:

Torrent Pharmaceuticals Ltd. provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Long-term investors can download Torrent Pharmaceuticals Ltd.'s investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Torrent Pharmaceuticals Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Torrent Pharmaceuticals Ltd.'s promoters include the promoters group and public shareholding. Long-term investors can use our pre-built screening tools to analyze Torrent Pharmaceuticals Ltd.'s promoter holdings and identify any potential conflicts of interest. The promoter holdings of Torrent Pharmaceuticals Ltd. are relatively stable, which is a positive sign for long-term investors.

Torrent Pharmaceuticals Ltd. Shareholders:

Torrent Pharmaceuticals Ltd. has a large number of shareholders, including institutional investors and individual investors. Long-term investors can use our pre-built screening tools to analyze Torrent Pharmaceuticals Ltd.'s shareholder base and identify any potential risks or opportunities. The shareholder base of Torrent Pharmaceuticals Ltd. is diverse, which is a positive sign for long-term investors.

Torrent Pharmaceuticals Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help long-term investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

Torrent Pharmaceuticals Limited ROCE

The Return on Capital Employed (ROCE) ratio measures the profitability of a company in relation to its capital employed. It is a useful ratio for investors to assess how efficiently a company is using its capital to generate profits. On the Torrent Pharmaceuticals Limited stock analysis page, you can find the ROCE ratio in the financials table or ratio section.

Torrent Pharmaceuticals Limited EBITDA

EBITDA is an abbreviation for Earnings Before Interest, Taxes, Depreciation, and Amortization. This is a helpful ratio for investors to evaluate a company's operating profitability. It helps in determining the potential for long-term cash flow generation. On the Torrent Pharmaceuticals Limited stock analysis page, the EBITDA ratio can be accessed easily through the financials table or ratio section.

Torrent Pharmaceuticals Limited DPS

The Dividend Per Share (DPS) ratio is an important financial metric that measures the total dividends given out per share outstanding. It indicates the amount of profit that the company has decided to share with its investors. This ratio is important for investors who are looking for a constant stream of income from their investments. The DPS ratio for Torrent Pharmaceuticals Limited can be found in the financials table or ratio section on its stock analysis page.

Torrent Pharmaceuticals Limited EPS

Earnings Per Share (EPS) ratio is a key measure of profitability that indicates how much profit a company produces for each outstanding share of stock. It is important for investors who want to evaluate the potential value of a company's stock. The EPS ratio for Torrent Pharmaceuticals Limited can be found in the financials table or ratio section on its stock analysis page.

Read More
X